NMU (104-114), Agonist of BB 3 receptor, CAS No.rp174641, Agonist of BB 3 receptor

CAS: rp174641 Cat. No.: rp174641

GRADE & PURITY Moligand™

Specifications

Product Name

NMU (104-114), Agonist of BB 3 receptor, CAS No.rp174641

Grade

Moligand™

Specifications & Purity

Moligand™

Action Type

AGONIST

Mechanism of action

Agonist of BB 3 receptor

CAS

rp174641

Molecule Type

Peptide

Product Line

Biological Products

Storage and Shipping

Storage

Room temperature

Associated Targets(Human)

BRS3 Tchem Bombesin receptor subtype-3 (0 Activities)

Discover Target: BRS3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Genetic information

• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

No item-specific, validated protocols are provided in the Product Data for NMU (104-114).

• General starting-point protocols (literature/general; adapt as needed)
  • Stock preparation: Dissolve at 1–10 mM in water or DMSO based on solubility; vortex and briefly sonicate if needed. Filter-sterilize (0.22 µm) for cell work.
  • Cell-based GPCR assay (example framework): Plate cells expressing the receptor of interest (e.g., NMUR1/2) 18–24 h prior. Prepare serial dilutions in assay buffer, targeting ≤1% DMSO final. Incubate with cells under assay-appropriate conditions (e.g., 30–60 min for β-arrestin; minutes for Ca2+ flux). Include reference peptide controls and vehicle.
  • Binding assay (example framework): Use a validated radioligand or fluorescent tracer. Incubate membranes or cells with tracer ± test peptide across a concentration range to determine competitive binding. Separate bound/free and analyze by non-linear regression.

These are generic templates to aid experimental planning. Optimize parameters and verify compatibility with your instrumentation and cell systems.

Biological Roles

• Item-specific biological claims are not provided in the Product Data. The following is general, literature-based context for neuromedin U (NMU) fragments and is not a specification for this item.

• Literature/general context

  • Neuromedin U (NMU) is a conserved neuropeptide family with endogenous activity at G protein–coupled receptors NMUR1 and NMUR2. Full-length NMU peptides (e.g., species-dependent NMU-8/9/25) modulate smooth muscle tone and central/peripheral signaling pathways in vertebrates (literature).
  • Short NMU-derived fragments corresponding to specific precursor regions (such as residues denoted “104–114”) are used as tool ligands to explore sequence determinants of receptor binding and activation, often assessing which minimal motifs are necessary/sufficient for activity.
  • Biological behavior of fragments depends on sequence, post-translational features (e.g., C-terminal amidation), and assay context (cell line, receptor expression level, peptidase environment). Some fragments retain partial activity, whereas others act as weak agonists/antagonists or are inactive (literature variability).

• Practical implications (general)

  • When designing experiments, benchmark against a validated reference NMU peptide to calibrate potency. Account for potential rapid proteolysis in serum-containing media and consider stability-enhancing conditions if needed.

All uses are for research only; no clinical or diagnostic applications are implied.

Buffer Applications

This product is a peptide-like screening ligand and is not itself a buffering agent.

• General handling in buffers (literature/general)
  • Dissolve in water or physiological buffers (e.g., PBS, HBSS) where compatible with the intended assay. Adjust pH modestly to favor solubility based on predicted ionization of the peptide.
  • For low-solubility sequences, prepare a concentrated DMSO stock and dilute into buffer immediately before use, maintaining a low final DMSO percentage (typically ≤1–2%).
  • Filter sterilize through 0.22 µm low-protein-binding membranes if sterile solutions are required for cell-based work.

No item-specific buffer recipes or pKa values are provided; consult the CoA/Spec Sheet for any available solubility notes.

Green Alternatives

This item is a peptide-like screening ligand rather than a process solvent or bulk reagent. “Green alternative” considerations are therefore limited.

• General guidance (literature/general)
  • Prefer aqueous buffers over organic solvents whenever assay design allows.
  • If co-solvents are required, use the minimum effective DMSO percentage and avoid halogenated solvents.
  • Scale reactions/assays to the smallest practical volume to reduce chemical footprint and waste.
  • Implement room-temperature storage and shipping (as permitted by product stability) to reduce cold-chain energy use; this item lists room-temperature storage in Product Data.

No item-specific greener substitutes apply; optimization should focus on solvent minimization and buffer-based formulations in the user’s workflow.

Pharmaceutical Uses

No pharmacopeial or excipient status is provided for this item. It is supplied strictly for research use only (per Product Data).

• Literature/general context

  • NMU-related peptides and fragments can serve as reference materials or tool compounds in non-clinical discovery, including receptor pharmacology, SAR exploration, and assay validation. They may also be used to generate standard curves or as positive controls in method development for bioanalytical assays.
  • Any consideration of formulation, dosing, or in vivo use falls outside the scope of this research-use product and must not be inferred from this listing.

• Practical notes

  • If used as a reference in regulated studies, ensure appropriate characterization (identity, purity, counterion, water content) and maintain controlled storage/handling records. Obtain batch-specific documentation from the CoA.

Physical Properties

Item-specific physicochemical specifications are not provided in the Product Data for NMU (104-114).

• Item-specific values

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point, boiling point, density, refractive index, UV cutoff, metal content, residual solvents: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general expectations for short peptides (for planning only; not item-specific specs)

  • Physical form: Typically supplied as a lyophilized solid or film; hygroscopicity varies with composition.
  • Solubility: Sequence-dependent; many short peptides dissolve in water, buffered saline, or aqueous dilute acid/base; hydrophobic sequences may require DMSO or co-solvent systems.
  • Charge state: pH-dependent due to ionizable termini/side chains; influences solubility and aggregation.
  • Partitioning (logP): Generally not applicable; peptides are better described by sequence-based hydropathy than by octanol/water partitioning.

Always consult the product’s CoA/Spec Sheet for definitive, item-specific properties prior to experimental design.

Quality & Grades

• Item-specific designation

  • Grade/Purity: Moligand™ (as provided)
  • The Moligand™ designation indicates inclusion in a screening-oriented compound/ligand library suitable for discovery workflows such as target engagement or receptor activation profiling. It does not, by itself, define chromatographic purity, counterion content, or residual solvent limits—consult the CoA/Spec Sheet for those specifics.

• What Moligand™ implies (general guidance)

  • Screening readiness: Typically packaged and formatted for HTS/HCS or biochemical/pharmacological assays. May be compatible with DMSO stock preparation and microplate dispensing (verify item-specific solubility and concentration limits).
  • Identity verification: Peptide library items are often characterized by LC–MS and, when applicable, HPLC purity assessment; details should be confirmed on the item’s certificate.
  • Stabilizers/salts: Peptides can be supplied as trifluoroacetate (TFA) salts or alternative counterions; presence/identity of counterions and any stabilizers are not specified for this item and should be checked on the CoA.

• Practical notes

  • For quantitative studies (e.g., potency curves), request or consult documentation on purity basis (by area vs. weight), counterion content, and water content to correctly calculate molar concentrations.
  • If ultra-low UV background or metal content is required, confirm suitability prior to use. Otherwise, treat Moligand™ as a research-use screening grade.

Reaction & Applications

This product is intended for research screening rather than synthetic transformation. No item-specific reaction applications are provided in the Product Data.

• General applications for NMU-derived peptide fragments (literature/general; not item-specific)

  • Receptor pharmacology: Neuromedin U peptides are endogenous ligands for NMUR1/NMUR2 GPCRs. Short fragments are often used as tool compounds in binding, signaling, or reporter assays to probe structure–activity relationships (SAR) and receptor activation profiles.
  • Assay types: Calcium flux, cAMP or IP1 accumulation, β-arrestin recruitment, ERK phosphorylation, and radioligand displacement assays. Fragment activity may vary substantially with sequence and terminal modifications; confirm with item-specific data.
  • Biophysical profiling: Surface plasmon resonance (SPR), microscale thermophoresis (MST), or thermal shift assays to assess target engagement, where applicable.

• Practical considerations (general)

  • Prepare fresh working solutions, minimize freeze–thaw cycles of concentrated stocks, and include appropriate vehicle controls (e.g., DMSO) and positive controls (reference peptide) for assay benchmarking.
  • Consider peptidase protection strategies in cell-based assays (e.g., use of serum-free conditions or protease inhibitors) if stability is limiting.

For synthetic organic reactions, this item is not typically used as a reagent; see Synthetic Utility for a brief note.

Reaction Conditions

Not typically applicable. NMU (104-114) is provided as a research ligand and not for use as a reagent in chemical transformations.

• Assay preparation conditions (general; not item-specific)
  • Prepare stock solutions in water, buffer, or DMSO as solubility permits. Work at ambient temperature and avoid prolonged exposure to elevated temperatures or extreme pH.
  • For cell-based assays, maintain physiological conditions (e.g., pH 7.2–7.4, standard incubation temperatures matching the cell system). Include vehicle controls corresponding to any co-solvent used.

No item-specific reaction or assay condition data are provided in the Product Data; consult the literature and validate conditions empirically.

Safety & Handling

• Product-specific safety information (from Product Data)

  • GHS Classification: Not specified for this item; refer to SDS.
  • Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.
  • Storage Conditions: Room temperature (as provided; see Storage & Reconstitution tab for additional guidance).

• General safety guidance for research peptides (literature/general; not item-specific)

  • Hazard profile: Many synthetic peptides are considered low volatility solids with low acute toxicity by dermal or inhalation routes; however, avoid inhalation of powders and contact with eyes/skin. Sensitization is possible with repeated exposure.
  • PPE: Laboratory coat, nitrile gloves, safety glasses; weigh in a fume hood or balance enclosure to minimize dust/aerosol exposure.
  • Handling tips: Allow vials to equilibrate to room temperature before opening to prevent condensation. Open gently to avoid aerosolization of lyophilizates.
  • Incompatibilities: Strong oxidants may degrade peptide side chains; avoid extreme pH and prolonged exposure to elevated temperatures.
  • First aid (overview): If inhaled, move to fresh air; if on skin/eyes, rinse with water for several minutes; if ingested, rinse mouth and seek medical advice. Provide the SDS to medical personnel.

Always defer to the official SDS and your institutional EHS protocols for authoritative hazard and response information.

Solvent Selection

• Item-specific solubility data: Not specified for this item; refer to CoA/Spec Sheet.

• General solvent strategy for short peptides (literature/general)

  • Primary choices: Start with ultrapure water or physiological buffers (e.g., PBS) at neutral pH. If insoluble, adjust pH slightly toward the predicted net charge (acidify for basic peptides; basify for acidic peptides).
  • Co-solvents: For hydrophobic sequences or those prone to aggregation, pre-wet with a minimal volume of DMSO (e.g., 5–20% final), acetonitrile/water mixtures, or include 0.1% TFA or 0.1% acetic acid to aid dissolution (assess compatibility with downstream assays).
  • Order of operations: Add solvent gradually with gentle vortexing/sonication. Avoid strong heating; prolonged temperatures >30–37°C can accelerate degradation.
  • Filtration: If particulate persists, use low-protein-binding 0.22 µm filters. Verify no peptide loss to membranes for low-concentration stocks.

• Comparison notes (general)

  • Water/buffer: Highest assay compatibility; may require pH tuning.
  • DMSO: Broad solubilizing power; maintain ≤1–2% in final bioassays to limit solvent effects.
  • Dilute acid/base: Useful to protonate/deprotonate termini/side chains; verify stability and assay tolerance.

Document final solvent composition in screening data packages to enable reproducibility.

Storage & Reconstitution

• Item-specific storage (from Product Data)

  • Storage Conditions: Room temperature.
  • Shipped In: Not specified for this item; refer to CoA/Spec Sheet.

• General guidance for peptides (literature/general; not item-specific)

  • If supplied lyophilized, room-temperature storage is often acceptable for short-term handling. For longer-term retention of activity, many users store peptides at 2–8°C (dry) or −20°C (desiccated); confirm with the item’s CoA before deviating from the provided guidance.
  • Upon first use, allow the vial to equilibrate to room temperature before opening to avoid condensation.

• Reconstitution (general)

  • Use molecular biology–grade water or appropriate buffer. Start with a small volume and gently vortex/sonicate. If needed, pre-wet with a minimal volume of DMSO before dilution into aqueous media.
  • Prepare aliquots to avoid repeated freeze–thaw. For aqueous stocks, store at −20°C when compatible; avoid more than 2–3 freeze–thaw cycles.
  • Record exact solvent composition and concentration for reproducibility.

Always consult the batch-specific CoA/Spec Sheet for definitive instructions on storage, handling, and reconstitution.

Structure & Identity

Brief overview: This listing refers to NMU (104-114), offered under Aladdin’s Moligand™ screening collection. Item-specific structural identifiers are not provided in the product data.

• Item-specific identifiers (from Product Data)

  • SKU: rp174641
  • Product Name: NMU (104-114)
  • CAS: rp174641 (catalog placeholder; not a CAS Registry Number)
  • InChIKey: 194358 (as provided; not a standard 27-character InChIKey)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (literature/general context)

  • “NMU (104-114)” is commonly used to denote a short peptide segment derived from the neuromedin U precursor sequence (literature). Such fragments are typically linear oligopeptides comprised of standard amino acids and may be supplied with free or protected termini (e.g., free acid, amide) depending on synthesis (literature; not item-specific).
  • Peptide fragments often contain amide bonds, potential ionizable side chains, and may display net positive/negative charge depending on sequence and pH (general peptide chemistry).

• 2D description (general for short peptides; not item-specific)

  • A backbone of repeating –NH–CH(R)–CO– units with side chains R corresponding to the amino-acid residues spanning the 104–114 region of the NMU precursor (literature concept). Terminal groups and any modifications are not specified for this item.

Synthetic Utility

This item is a peptide-like screening ligand and is not typically employed as a general synthetic reagent or building block in small-molecule chemistry.

• General notes (literature/general)
  • Peptides can, in principle, serve as affinity probes or be incorporated into conjugates (e.g., fluorophore- or biotin-labeled derivatives) for assay development; however, such modifications would be custom operations beyond the scope of this catalog item.
  • If derivatization is desired, standard peptide coupling chemistries (e.g., NHS ester labeling of lysine side chains, maleimide–thiol conjugation for cysteine) may be applicable depending on sequence—sequence details for this item are not provided.

For routine organic synthesis (e.g., cross-couplings, nucleophilic substitutions), this product has limited utility compared with dedicated reagents.

Target Specificity

• Item-specific target details are not provided in the Product Data. No antigen, epitope, clone, isotype, or species reactivity information applies to this product, as it is not an antibody.

• General note (literature)

  • Neuromedin U peptides engage NMUR1/NMUR2 receptors; however, the activity and selectivity of a specific fragment such as “104–114” depend on its exact sequence and modifications, which are not specified for this item. Do not assume target potency or selectivity without experimental confirmation for the supplied lot.